Overview
Rapact 5 mg contains Everolimus, a targeted cancer therapy that belongs to the mTOR inhibitor class. It is primarily used in the treatment of various cancers such as advanced kidney cancer (renal cell carcinoma), breast cancer, neuroendocrine tumors, and tuberous sclerosis complex (TSC)-related tumors. Everolimus works by blocking the mTOR pathway, which is crucial for cancer cell growth and proliferation.





